JCEM: Interactions between anemia in healthy adults, FGF-23, and bones.

Osteoporosis and anemia are the most common diseases among older people, and their prevalence rates are on the rise worldwide.
As a result of recent reports that bone-derived hormone-fibroblast growth factor 23 (FGF-23) regulates red blood cell production, a recent study was published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, to assess the age-related correlation between hemoglobin levels and bone mass, bone transformation, and FGF-23 concentrations.
researchers used data from more than 5,000 adult subjects who participated in a population-based queue in the PO MELANIA Health Study (SHIP and SHIP-Trend).
researchers assessed bone mass through quantitative ultrasound of the heel, and assessed bone renewal by measuring the serum concentration of the end-end peptides of type I collagen (CTX) and P1NP complete amino end-end peptides, respectively.
anemia is defined as male hemoglobin,13 g/dl, female-lt;12 g/dl.
researchers measured FGF-23C end levels in the plasma of 852 subjects.
compared with non-anemia subjects, anemia subjects had poor bone mass, higher risk of fractures, and lower Serum levels of P1NP.
linear regression model found a positive correlation between hemoglobin and bone mass in subjects 40 years of age or older, and a negative correlation with CTX in subjects 60 years of age or older.
hemoglobin and FGF-23 concentrations were negatively related, while FGF-23 levels were independent of bone mass or turnover.
the study confirmed a strong relationship between FGF-23 and anemia, which is associated with poor bone mass in older adults.
, however, the researchers did not observe a direct association between FGF-23 levels and bone parameters.
further research is needed to clarify the role of FGF-23 in bone and red blood cell production.
.